Recent advances in cancer therapeutics

Area of Science:

• Oncology
• Medicinal Chemistry
• Drug Discovery

Background:

• Cancer therapeutics have shifted from traditional cytotoxic drugs to targeted therapies.
• Imatinib, a kinase inhibitor, exemplifies this paradigm shift, targeting specific cancer-driving proteins.
• The goal is to achieve high efficacy with reduced toxicity.

Purpose of the Study:

• To review advancements in targeted cancer therapeutics.
• To highlight novel approaches in medicinal chemistry for oncology drug discovery.
• To focus on four key areas: chaperone inhibitors, kinase inhibitors, histone deacetylase inhibitors, and protein-protein interaction inhibitors.

Main Methods:

• Review of approved drugs and clinical trials in selected therapeutic areas.
• Emphasis on high-throughput screening, fragment-based screening, and structure-based design.
• Exploration of selectivity, pharmacokinetic optimization, and pharmacodynamic biomarker modulation.

Main Results:

• Imatinib demonstrates impressive survival improvements in chronic myeloid leukemia patients.
• Selected areas showcase newer approaches and novel aspects of medicinal chemistry in cancer treatment.
• Compounds in these areas are either approved drugs or in clinical trials.

Conclusions:

• Targeted therapies represent a significant advancement in cancer treatment.
• Medicinal chemistry plays a crucial role in developing effective and less toxic cancer drugs.
• Continued innovation in drug discovery is essential for improving patient outcomes.